Pre Market
|
||||
|
|
|
|
Regular Hours
|
|
|
|
|
||||||||||||
|
|
|
|
|
|
|
|
| Valuation Estimation |
|
EPS (Current/Estimated)
-2.92/-3.51
|
|
Enterprise Value
2.95B
|
| Balance Sheet |
|
Book Value Per Share
2.43
|
| Cash Flow |
|
Cash Flow Yield
--
|
| Income Statement |
|
Total Revenue
0
|
|
Operating Revenue Per Share
--
|
|
Industry Comparison
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Quotes are at least 15-min delayed:2025/11/17 07:35 EST
Industry overview quotes are at least 15 minutes delayed
|
Business Description
|
|||
| Scholar Rock Holding Corp is a late-stage biopharmaceutical company focused on discovering, developing, and delivering innovative medicines for treating serious diseases in which signaling by protein growth factors plays a fundamental role. Its pipeline includes Neuromuscular and Obesity, Immuno-oncology, Fibrotic Disease, and Hematology. The group operates and manages its business as a single segment to assess performance and make operating decisions. |

37.3 

37.41